SCHEMBL3815379

SCHEMBL3815379

Cc1ccc2oc(Nc3ccc(-c4cn(C5CCC(N6CCNC(=O)C6)CC5)c5ncnc(N)c45)cc3F)nc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.63
ERBB2 P04626 4/20 0.63
IGF1R P08069 4/20 0.63
ERBB3 P21860 4/20 0.63
ERBB4 Q15303 4/20 0.63
NEK7 Q8TDX7 12/20 0.49
RIPK2 O43353 3/20 0.45
PDGFRB P09619 1/20 0.45
KIT P10721 1/20 0.45
SRC P12931 1/20 0.45
FLT3 P36888 1/20 0.45
SIK1 P57059 1/20 0.45
RIPK4 P57078 1/20 0.45
DDR1 Q08345 1/20 0.45
RIPK1 Q13546 1/20 0.45
DSTYK Q6XUX3 1/20 0.45
RIPK3 Q9Y572 1/20 0.45
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
PIKFYVE Q9Y2I7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3815384 1.00 EGFR (0.63) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL4820107 0.87 IGF1R (0.67) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL4820117 0.87 IGF1R (0.67) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL4824623 0.87 IGF1R (0.67) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL3816347 0.86 EGFR (0.62) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6109590 0.82 EGFR (0.75) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6109588 0.82 EGFR (0.75) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6108958 0.80 EGFR (0.82) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL3818589 0.80 EGFR (0.82) EGFRERBB2IGF1RERBB3ERBB4
SCHEMBL6867289 0.80 EGFR (0.75) EGFRERBB2IGF1RERBB3ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730148-A4 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LAB (US) 2009-08-19 EP disclosed
EP-1730148-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2006-12-13 EP disclosed
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 US disclosed
WO-2005074603-A2 AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 EGFR 506/4885ERBB2 47/4885IGF1R 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.